Reneo faces two shareholder lawsuits over OnKure merger proxy; provides supplemental disclosures

OnKure Therapeutics, Inc.

Two complaints filed in NY Supreme Court allege misrepresentations/omissions in proxy regarding financial projections and advisor conflicts.
Reneo denies allegations but voluntarily supplements proxy with details on Leerink's $40k prior compensation and 5% aggregate placement agent fee.
Supplemental disclosures include unadjusted OnKure forecasts showing projected net sales up to $3B by 2042 and DCF equity value range of $180M-$290M.
Reneo confirms no internal liquidation analysis was prepared; board relied on OnKure forecasts and $15M enterprise value ascribed to Reneo.
Merger and concurrent PIPE expected to close; company intends to vigorously defend against litigation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.